Captor Therapeutics

      by nature

      We are reprogramming protein
      fate to treat the untreatable.


      who are we?

      About us

      Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

      Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”.

      Captor Therapeuticsis a Swiss-Polish company with offices in Basel, Switzerland and operations in state-of-the-art laboratories in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.

      what are we doing?


      Since millions of years ago fitohormones (e.g. auxins) have been reprograming TIR1 E3 ubiquitin ligase to change its ubiquitylation and degradation specificity.

      • 1999

        Kenten J. and Roberts S. filed a patent application for compounds activating ubiquitination of a target protein. An idea of Ubiquitin Proteasome System modulation emerged.

      • 2001

        Proof of Principle - targeted protein degradation with peptidic bifunctional moleculewas reported (Sakamoto K. et al., PNAS).

      • 2004

        Nobel Prize in Chemistry was awarded for the discovery of ubiquitin-mediated protein degradation (Aaron Ciechanover, Avram Hershko and Irwin Rose).

      • 2008

        First small molecule bifunctional degrader was reported (Smith A. et al., Bioorg. Med. Chem. Lett.).

      • 2010

        Cereblon E3 ubiquitin ligase complex was identified as thalidomide’s target. The discovery fuelled progress in a Targeted Protein Degradation technology (Ito T. et al., Science).

      • 2017

        Obterons™ at Captor Therapeutics – direct degraders inspired by nature.

        what's next?

      what are we doing?

      Our approach

      Thanks to our expertise in targeted protein degradation we take a multi-faceted approach to eliminate pathological proteins. Our technology consists of bifunctional molecules and direct degraders.

      Our proprietary Obteron™ platform enables the robust discovery of therapeutic compounds with good biopharmaceutical properties. These compounds lead to efficient protein degradation via proteasome and/or autophagosome.

      Supported by over 44 mln EUR from European grants and private investors, we are currently working on several projects aiming at (1) advancement of a protein degradation platform and (2) development of first-in-class therapeutics for autoimmune and oncological indications.

      stay in touch


      Captor Therapeutics Inc
      ul. Duńska 11
      54-427 Wrocław, Poland

      Captor Therapeutics GmbH
      Gewerbestrasse 24
      4123 Allschwil, Switzerland

      Write us a message

      • Poland
      • Switzerland